4-氰基-4-(((乙硫基)硫代羰基)硫基)戊酸 | 1137725-46-2

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 4-氰基-4-(((乙硫基)硫代羰基)硫基)戊酸
• 英文名称: 4-cyano-4-(ethylsulfanylthiocarbonyl)sulfanylpentanoic acid
• 英文别名: 4-cyano-4-(((ethylthio)carbonothioyl)thio)pentanoic acid；ECT；4-Cyano-4-[(ethylsulfanylthiocarbonyl)sulfanyl]pentanoic acid；4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid
• CAS: 1137725-46-2
• 化学式: C₉H₁₃NO₂S₃
• 分子量: 263.406
• InChiKey: KEWSCDNULKOKTG-UHFFFAOYSA-N

物化性质

• 沸点：
  490.7±45.0 °C(Predicted)
• 密度：
  1.329±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  15
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  144
• 氢给体数：
  1
• 氢受体数：
  6

安全信息

• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  室温下应存放在干燥密封的环境中。

反应信息

• 作为反应物：
  描述：

  4-氰基-4-(((乙硫基)硫代羰基)硫基)戊酸 在 2-(dimethylamino)pyridinium p-toluenesulfonate 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 10.0h， 生成 6-cyano-6-methyl-9-oxo-4-thioxo-10,13-dioxa-3,5-dithiapentadecan-15-yl 6-oxo-6-(2-thioxothiazolidin-3-yl)hexanoate
  参考文献：
  名称：

  Synthesis, Characterization, and Bioactivity of Mid-Functional PolyHPMA−Lysozyme Bioconjugates

  摘要：

  A thiazolidine-2-thione mid-functionalized chain transfer agent (CTA) was synthesized and used as a reversible addition fragmentation chain transfer (RAFT) polymerization agent to prepare poly(N-(2-hydroxypropyl)methacrylamide) (polyHPMA) with mid-chain thiazolidine-2-thione functionality. The synthesized polymers were fully analyzed by H-1 NMR and GPC, confirming well-defined structures (predesigned molecular weights, narrow polydispersities, and high functionalization efficiencies). A subsequent hydrolysis/analysis of the polymers was performed to verify their mid-functional structures. These mid-functionalized polymers were then incubated with a model protein (lysozyme) to generate branched polymer protein bioconjugates. The bioactivity of the branched polymer protein conjugate was tested and compared to similar molecular weight linear polyHPMA-protein bioconjugate; the branched polymer protein conjugate remained much more protein activity, indicating the mid-chain-functional polyHPMA was more selective in its conjugation reaction on the lysozyme surface when compared with conjugation reactions involving terminal-functional polyHPMA. This straightforward methodology, described herein, for the synthesis of branched polymer protein bioconjugates strikes a balance between protein protection by the attachment of polymer chains and the subsequent bioactivity retention of the bioconjugate.

  DOI：

  10.1021/ma100142w
• 作为产物：
  描述：

  bis(ethylsulfanyl thiocarbonyl)disulfide 、 4,4'-偶氮双(4-氰基戊酸) 以 乙酸乙酯 为溶剂， 以88%的产率得到4-氰基-4-(((乙硫基)硫代羰基)硫基)戊酸
  参考文献：
  名称：

  温度响应性聚合物支撑的TEMPO：一种有效且可回收的催化剂，用于醇的选择性氧化

  摘要：

  这项研究旨在通过将TEMPO固定在水溶性温度响应性聚合物中来结合均相催化和非均相催化的优势。负载的TEMPO是水溶性的，并且在LCST以下的醇的选择性氧化中表现出出色的活性，可以轻松回收。

  DOI：

  10.1016/j.tetlet.2018.12.051

文献信息

• [EN] HYDROPHILIC POLYMER CONJUGATE WITH MULTIPLE ANTIVIRAL AGENTS FOR TREATING A VIRAL INFECTION<br/>[FR] CONJUGUÉ POLYMÈRE HYDROPHILE À PLUSIEURS AGENTS ANTIVIRAUX POUR LE TRAITEMENT D'UNE INFECTION VIRALE
  申请人：COMMW SCIENT IND RES ORG

  公开号：WO2017205901A1

  公开（公告）日：2017-12-07

  The present invention relates to a hydrophilic polymer conjugate comprising multiple antiviral agents for treating viral infections. The present invention also relates to methods of treating viral infections, in particular, human immunodeficiency virus (HIV) infection, by administration of a hydrophilic polymer conjugate comprising multiple antiviral agents. The polymer conjugates may be useful in combination therapy for the treatment of HIV.

  本发明涉及一种含有多种抗病毒药物的亲水性聚合物共轭物，用于治疗病毒感染。本发明还涉及通过给予含有多种抗病毒药物的亲水性聚合物共轭物来治疗病毒感染的方法，特别是人类免疫缺陷病毒（HIV）感染。这些聚合物共轭物可能在HIV治疗的联合疗法中有用。
• Protein Release from Biodegradable PolyHPMA-Lysozyme Conjugates Resulting in Bioactivity Enhancement
  作者：Lei Tao、Gaojian Chen、Lixiang Zhao、Jiangtao Xu、Edwin Huang、Aiping Liu、Christopher P. Marquis、Thomas P. Davis

  DOI：10.1002/asia.201000729

  日期：2011.6.6

  polymer chain ends fixed by biodegradable disulfide bonds. The functional polyHPMA chains were subsequently conjugated to protein (lysozyme) by exploiting reactions between the thiazolidine‐2‐thione functionality and amine residues on the protein surface to form covalent amide linkages. The in vitro bioactivities of the lysozyme–polyHPMA conjugates were assessed by using Micrococcus lysodeikticus cells

  合成了一种新型的可生物降解的噻唑烷-2-硫酮功能链转移剂，并将其用作可逆的附加断裂链转移剂，以制备具有预定分子量和窄多分散性的明确定义的半遥远的聚-N-（2-羟丙基）甲基丙烯酰胺（polyHPMAs）。 。蛋白质反应性基团噻唑烷-2-硫酮位于通过可生物降解的二硫键固定的聚合物链末端。随后，利用噻唑烷-2-硫酮官能团与蛋白质表面的胺残基之间的反应，将功能性的聚HPMA链与蛋白质（溶菌酶）偶联，形成共价酰胺键。用溶菌微球菌评估了溶菌酶-polyHPMA偶联物的体外生物活性。细胞作为底物。缀合过程后，溶菌酶的生物活性显着降低。但是，从生物结合物中裂解聚合物链（在还原条件下）会产生游离蛋白并显着恢复生物活性。通过对小鼠皮下注射进行体内测试，并清楚地证明与天然蛋白相比，蛋白质-聚合物结合物的蛋白水解降解降低，表明通过结合策略可有效保护蛋白质。这种生物可逆的偶联方法可以在蛋白质保护和有效的生物活性维持之间取得平衡。
• [EN] BLOCK COPOLYMERS AND THEIR CONJUGATES OR COMPLEXES WITH OLIGONUCLEOTIDES<br/>[FR] COPOLYMÈRES SÉQUENCÉS ET LEUR CONJUGUÉS OU COMPLEXES AVEC DES OLIGONUCLÉOTIDES
  申请人：PHASERX INC

  公开号：WO2015017519A1

  公开（公告）日：2015-02-05

  Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed.

  本文描述了嵌段共聚物以及制备和利用这种共聚物的方法。所述的嵌段共聚物破坏细胞膜，包括细胞外膜、细胞内膜、囊泡、细胞器、内体、脂质体或红细胞。在某些情况下，该嵌段共聚物会破坏膜并进入细胞内环境。在具体示例中，该嵌段共聚物具有内体溶解作用，并能够将寡核苷酸（例如mRNA）传递到细胞中。还公开了包含嵌段共聚物和寡核苷酸（例如mRNA）的组合物。
• Polymeric prodrugs and subcutaneous and/or intramuscular administration thereof
  申请人：CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

  公开号：US20200353090A1

  公开（公告）日：2020-11-12

  The invention relates to new prodrugs of active molecules. These prodrugs allow, in particular, the subcutaneous or intramuscular administration of active molecules of which the subcutaneous or intramuscular administration is problematic or impossible, in particular because of the toxicity at the injection site. The prodrugs according to the invention comprise an active ingredient, covalently linked with a polymer chain, preferably a hydrophilic and/or thermosensitive polymer chain. The invention relates, in particular, to polymeric prodrugs comprising a polymer chain formed at least in part by acrylamide monomer or one of its derivatives, the polymer comprising a proximal part and a terminal part; a first pharmaceutically active molecule covalently coupled to the proximal part of the polymer; possibly a second pharmaceutically active molecule covalently coupled to the terminal part of the polymer.

  该发明涉及新型活性分子的前药。这些前药允许特别是将活性分子皮下或肌肉内注射，而这些活性分子的皮下或肌肉内注射由于在注射部位的毒性而具有问题或不可能，特别是由于在注射部位的毒性。根据本发明的前药包括一种活性成分，与一根聚合物链共价连接，优选为一种亲水性和/或热敏感性聚合物链。该发明特别涉及包括由丙烯酰胺单体或其衍生物之一至少部分形成的聚合物链的聚合物前药，该聚合物包括一个近端部分和一个末端部分；第一种药用活性分子共价结合到聚合物的近端部分；可能第二种药用活性分子共价结合到聚合物的末端部分。
• ISOSORBIDE-BASED POLYMETHACRYLATES
  申请人：Hillmyer Marc A.

  公开号：US20160229863A1

  公开（公告）日：2016-08-11

  A monomer comprises the structure wherein R 1 comprises H or a substituted hydrocarbyl or unsubstituted hydrocarbyl, and wherein R 2 comprises H, a halide, or a substituted or unsubstituted (C 1 -C 4 ) hydrocarbyl. A method comprises (a) reacting a dianhydrohexitol precursor having the structure with an acyl-group containing compound having the structure wherein R 1 comprises H or a substituted hydrocarbyl or unsubstituted hydrocarbyl, and X comprises a halide, a hydroxyl group, or an acyl group to form an acylated dianhydrohexitol ester intermediate having the structure and (b) reacting the acylated dianhydrohexitol ester intermediate with an acrylic-based compound having the structure wherein R 2 comprises H, a halide, or a substituted or unsubstituted (C 1 -C 4 ) hydrocarbyl, and Y comprises a halide, a hydroxyl group, or an acyl group, to form a dianhydrohexitol-based monomer having the structure

  一个单体包括结构，其中R1包括H或取代的烃基或未取代的烃基，R2包括H，卤素，或取代或未取代的（C1-C4）烃基。一种方法包括（a）将具有结构的二酮六醇前体与具有结构的含酰基化合物反应，其中R1包括H或取代的烃基或未取代的烃基，X包括卤素，羟基，或酰基，形成具有结构的酰化二酮六醇酯中间体，和（b）将酰化二酮六醇酯中间体与具有结构的丙烯基化合物反应，其中R2包括H，卤素，或取代或未取代的（C1-C4）烃基，Y包括卤素，羟基，或酰基，形成具有结构的二酮六醇基单体。